Figure 3.
Glofitamab treatment induces spatial reorganization of CD8+ T cells in tumors. Images represent CD8+ (green), Ki67+ (pink), and 4′,6-diamidino-2-phenylindole (blue) immunofluorescence analysis of 3 DLBCL core biopsy specimens at baseline (BSL; before obinutuzumab pretreatment) and during treatment (OT). OT biopsy samples were taken on the first day of the second cycle (predose) (A and C) and on the eighth day of the third cycle (B). The insets in panel A indicate proliferative tumor cores (i), CD8+ T-cell area surrounding the core (ii), and area of necrosis (iii). The inset in panel B shows tumor cells (pink) interspersed and in close contact with CD8+ T cells (green). The OT biopsy in panel C is completely necrotic.

Glofitamab treatment induces spatial reorganization of CD8+ T cells in tumors. Images represent CD8+ (green), Ki67+ (pink), and 4′,6-diamidino-2-phenylindole (blue) immunofluorescence analysis of 3 DLBCL core biopsy specimens at baseline (BSL; before obinutuzumab pretreatment) and during treatment (OT). OT biopsy samples were taken on the first day of the second cycle (predose) (A and C) and on the eighth day of the third cycle (B). The insets in panel A indicate proliferative tumor cores (i), CD8+ T-cell area surrounding the core (ii), and area of necrosis (iii). The inset in panel B shows tumor cells (pink) interspersed and in close contact with CD8+ T cells (green). The OT biopsy in panel C is completely necrotic.

Close Modal

or Create an Account

Close Modal
Close Modal